Kevin Dack joined Pfizer UK in 1982 after studying chemistry at the University of Southampton. During his almost 30 years at the Sandwich Labs, Kevin was an inventor or contributor for over 15 nominated candidates, including two marketed drugs (voriconazole & darifenacin), with more than 50 publications and patents. As an associate research fellow, Kevin was actively involved in partnering with the Pfizer Compound Safety Prediction group to help establish a 'Compound Safety Evaluation Toolkit' that included avoiding drug/target promiscuity as a driver for safer drugs. Kevin is a fellow of the Royal Society of Chemistry (FRSC) and a Chartered Chemist (CChem), and he was awarded a Technical Achievement in organic chemistry (TAOC) by the ACS in 2007. In 2011, Kevin moved to Copenhagen, Denmark to join LEO Pharma, specializing in dermatology. He is currently the drug technology lead at LEO Global Research, with interests that include oral small-molecule, protein-protein interaction inhibitors and topical 'soft drug' design.